Objective：To determine the impact of adjunctive Buchang Naoxintong Capsule（步心脑心通胶囊,NXT） on dual antiplatelet therapy in patients with cytochrome P450 2C19＊2（CYP2C19＊2） polymorphism undergoing percutaneou...Objective：To determine the impact of adjunctive Buchang Naoxintong Capsule（步心脑心通胶囊,NXT） on dual antiplatelet therapy in patients with cytochrome P450 2C19＊2（CYP2C19＊2） polymorphism undergoing percutaneous coronary intervention（PCI）.Methods：Ninety patients with CYP2C19＊2 polymorphism were enrolled,and their genotypes were confirmed by polymerase chain reaction（PCR）.The patients were randomly assigned to receive either adjunctive NXT（triple group,45 cases） or dual antiplatelet therapy（dual group,45 cases） using a computer-generated randomization sequence and sealed envelopes.Platelet function was assessed at baseline and 7 days after treatment with conventional aggregometry.Subsequent major adverse cardiovascular events（MACE,including sudden cardiac arrest and acute coronary syndrome） were recorded during a 12-month followup.Results：Baseline platelet function measurements were similar in both groups.After 7 days,percent inhibitions of maximum platelet aggregation and late platelet aggregation were significantly greater in the triple versus dual group（42.3%±16.0%vs.20.8%±15.2%,P〈0.01,and 54.7%±18.3%vs.21.5%±29.2%,P〈0.01,respectively）.During the 12-month follow-up,the rate of subsequent MACE（6/45） was significantly lower in the triple group compared with the dual group（14/45;P〈0.05）.Conclusion：Adjunctive NXT to maintenance dose clopidogrel（75 g） could enhance the antiplatelet effect and decrease subsequent MACE in patients with the CYP2C19＇2polymorphism undergoing PCI.展开更多
基金Supported by the Provincial Natural Science Foundation of Fujian(No.2011J0133)the National Natural Science Foundation of China(No.81373838)
文摘Objective：To determine the impact of adjunctive Buchang Naoxintong Capsule（步心脑心通胶囊,NXT） on dual antiplatelet therapy in patients with cytochrome P450 2C19＊2（CYP2C19＊2） polymorphism undergoing percutaneous coronary intervention（PCI）.Methods：Ninety patients with CYP2C19＊2 polymorphism were enrolled,and their genotypes were confirmed by polymerase chain reaction（PCR）.The patients were randomly assigned to receive either adjunctive NXT（triple group,45 cases） or dual antiplatelet therapy（dual group,45 cases） using a computer-generated randomization sequence and sealed envelopes.Platelet function was assessed at baseline and 7 days after treatment with conventional aggregometry.Subsequent major adverse cardiovascular events（MACE,including sudden cardiac arrest and acute coronary syndrome） were recorded during a 12-month followup.Results：Baseline platelet function measurements were similar in both groups.After 7 days,percent inhibitions of maximum platelet aggregation and late platelet aggregation were significantly greater in the triple versus dual group（42.3%±16.0%vs.20.8%±15.2%,P〈0.01,and 54.7%±18.3%vs.21.5%±29.2%,P〈0.01,respectively）.During the 12-month follow-up,the rate of subsequent MACE（6/45） was significantly lower in the triple group compared with the dual group（14/45;P〈0.05）.Conclusion：Adjunctive NXT to maintenance dose clopidogrel（75 g） could enhance the antiplatelet effect and decrease subsequent MACE in patients with the CYP2C19＇2polymorphism undergoing PCI.
文摘目的探讨短暂性脑缺血发作(transient ischemic attacks,TIA)患者采用负荷剂量氯吡格雷治疗的临床效果。方法选取2020年6月—2022年6月厦门市第五医院收治的88例TIA患者。以随机数字表法分为研究组(n=44)和对照组(n=44)。2组均接受了血管扩张剂和神经保护药物等治疗,对照组给予常规剂量氯吡格雷治疗,研究组给予负荷剂量氯吡格雷治疗。比较2组临床疗效、神经功能、预后及不良反应。结果研究组的治疗总有效率(95.45%)高于对照组(79.55%)(P<0.05)。2组在治疗1、2周后,美国国立卫生研究院卒中量表(National Institutes of Health stroke scale,NIHSS)评分都有所降低(P<0.05),研究组治疗1、2周后NIHSS评分低于对照组(P<0.05)。2组治疗后改良Rankin量表(modified Rankin scale,mRS)评分降低(P<0.05),研究组评分低于对照组(P<0.05)。研究组不良反应总发生率(6.82%)与对照组(11.36%)比较,差异无统计学意义(P>0.05)。结论TIA患者采用负荷剂量氯吡格雷治疗具有确切的临床疗效,可有效改善神经功能及预后,且不会增加药物不良反应,体现了《短暂性脑缺血发作与轻型卒中抗血小板治疗中国专家共识》的执行标准。
